Understanding how cell interactions contribute to lung disease fibrosis
Official title: Cell-cell and cell-matrix interactions driving progressive fibrosis in interstitial lung diseases
Funded at University of California Los Angeles · NIH-10975694 · Data updated 2026-11-12
This study is looking at how different cells in the lungs work together to cause scarring in interstitial lung diseases, especially in the early stages, to help find new ways to treat the condition.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $822,275 |
| NIH project number | 1U01HL175451-01 |
| Project ID | NIH-10975694 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with interstitial lung diseases, particularly those in the early stages of the condition.
✕Less likely to help
Patients with advanced or end-stage interstitial lung disease may not benefit from this research as it focuses on early disease mechanisms.
What this research studies
This research investigates the mechanisms behind progressive fibrosis in interstitial lung diseases (ILDs) by examining the interactions between airway epithelial cells, mesenchymal cells, and the surrounding matrix. Using advanced techniques like spatial transcriptomics and 3D cell culture models, the study aims to explore how these cellular interactions drive the progression of fibrosis at different stages of the disease. By focusing on early ILD lesions, the research seeks to uncover the initiating factors that contribute to lung damage and fibrosis, potentially leading to new therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients suffering from interstitial lung diseases.
How similar studies have gone: While there has been significant research on end-stage ILD, this approach focusing on early lesions and cellular interactions is relatively novel and has not been extensively tested.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Gomperts, Brigitte N — University of California Los Angeles
- Study coordinator: Gomperts, Brigitte N
Related research
Other NIH-funded projects on the same topics.
-
How lung cells and their surroundings drive fibrosis in interstitial lung diseases
A study to understand how airway cells, surrounding tissue, and their environment contribute to progressive scarring in interstitial lung diseases.
-
How lung cell and tissue interactions cause scarring in interstitial lung disease
This project looks at how injured lung lining cells talk with nearby cells and the surrounding tissue to cause scarring in people with interstitial lung disease.
-
Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information.
This study is looking to help people with Idiopathic Pulmonary Fibrosis (IPF) by using their genetic information to find the best treatments for them, so they can get care that’s more personalized and effective.
-
Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information
This study is looking to make treatments for Idiopathic Pulmonary Fibrosis (IPF) better by using genetic information to find out how different people respond to medications like N-Acetylcysteine, so that doctors can provide more personalized care for patients with lung diseases.
-
Investigating the role of the complement pathway in lung diseases
This study is looking at how certain proteins in your body might help us understand the progression of idiopathic pulmonary fibrosis and similar lung diseases, so we can find better treatments tailored just for you.
-
Quantitative Ultrasound for Lung Diseases in People
A new ultrasound approach to measure how bad heart- or fibrosis-related lung problems are, using real-time, noninvasive imaging in people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.